AMRN Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q4

FY2026Q1

50.62M

-18.76%

-0.430

-64.18%

42.76M

+1.78%

-0.010

-99.58%

40.99M

-43.66%

0.000

-100%

Estimates Revision

The market is revising Upward the revenue expectations for Amarin Corporation plc (AMRN) for FY2025, with the revenue forecasts being adjusted by 11.49% over the past three months. During the same period, the stock price has changed by -5.22%.

Revenue Estimates for FY2025

Revise Upward

+11.49%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-94.24%

In Past 3 Month

Stock Price

Go Down

-5.22%

In Past 3 Month

1 Analyst Rating

Wall Street analysts forecast AMRN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for AMRN is 10.00 USD with a low forecast of 10.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

1 Hold

0 Sell

Hold

Current: 14.150

Low

10.00

Averages

10.00

High

10.00

Current: 14.150

Low

10.00

Averages

10.00

High

10.00

Goldman Sachs

Paul Choi

Strong Sell

Maintains

$20 → $7

2025-04-17

Reason

Goldman Sachs

Paul Choi

Price Target

$20 → $7

2025-04-17

Maintains

Strong Sell

Reason

Valuation Metrics

The current forward P/E ratio for Amarin Corporation PLC (AMRN.O) is -717.00, compared to its 5-year average forward P/E of -59.50. For a more detailed relative valuation and DCF analysis to assess Amarin Corporation PLC 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-59.50

Current PE

-717.00

Overvalued PE

114.08

Undervalued PE

-233.09

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-115.41

Current EV/EBITDA

-1.25

Overvalued EV/EBITDA

225.20

Undervalued EV/EBITDA

-456.02

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

2.18

Current PS

1.72

Overvalued PS

3.07

Undervalued PS

1.28

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

AMRN News & Events

Events Timeline

No data

News

4.0

12-09NASDAQ.COM

Daily Upgrade Report for Validea Kenneth Fisher Strategy - December 9, 2025

9.0

11-09Yahoo Finance

New Analysis from REDUCE-IT® on Aspirin Unveiled at AHA Scientific Sessions 2025 Confirms VASCEPA®/VAZKEPA® (Icosapent Ethyl) Lowers Cardiovascular Events in High-Risk Individuals

8.5

10-29NASDAQ.COM

GNTA, BBIO, AMRN Surge in After-Hours Trading: Major Biotech Factors Fueling Stock Increases

People Also Watch

Frequently Asked Questions

What is Amarin Corporation PLC (AMRN) stock price today?

The current price of AMRN is 14.15 USD — it has decreased -1.46 % in the last trading day.

What is Amarin Corporation PLC (AMRN)'s business?

Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.

What is the price predicton of AMRN Stock?

What is Amarin Corporation PLC (AMRN)'s revenue for the last quarter?

Amarin Corporation PLC revenue for the last quarter amounts to 49.67M USD, increased 17.43 % YoY.

What is Amarin Corporation PLC (AMRN)'s earnings per share (EPS) for the last quarter?

Amarin Corporation PLC. EPS for the last quarter amounts to -0.37 USD, decreased -69.67 % YoY.

What changes have occurred in the market's expectations for Amarin Corporation PLC (AMRN)'s fundamentals?

How many employees does Amarin Corporation PLC (AMRN). have?

Amarin Corporation PLC (AMRN) has 275 emplpoyees as of December 15 2025.

What is Amarin Corporation PLC (AMRN) market cap?

Today AMRN has the market capitalization of 298.58M USD.